Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences

Jun 10, 2016, 07:45 ET from Chelmsford Park SA

NEW YORK, June 10, 2016 /PRNewswire/ --

On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:

Pacific Biosciences of California Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The stock gained 1.55% to close the day at $9.80. The Company's stock recorded a trading volume of 3.71 million shares, which was above its three months average volume of 1.59 million shares. The Company's shares have gained 10.73% in the last one month and 24.52% in the previous three months. Furthermore, the stock has surged 68.10% in the past one year. The stock is trading 5.67% and 12.47% above its 50-day and 200-day moving averages, respectively. Additionally, Pacific Biosciences of California's stock has a Relative Strength Index (RSI) of 58.26. Sign up and read the free notes on PACB at:

On Thursday, shares in Tustin, California headquartered biopharma Company, Peregrine Pharmaceuticals Inc., ended the day 7.80% lower at $0.46 with a total volume of 1.34 million shares traded. The Company's shares have surged 39.70% in the last one month and 15.25% in the previous three months. The stock is trading above its 50-day moving average by 16.89%. Furthermore, shares of Peregrine Pharmaceuticals have an RSI of 60.27. The complimentary notes on PPHM can be downloaded in PDF format at:

On Thursday, shares in Berkeley, California headquartered clinical-stage biopharma Company, Dynavax Technologies Corp., ended the session 6.87% lower at $15.05 with a total volume of 890,801 shares traded. The stock is trading 16.38% below its 50-day moving average. Moreover, shares of Dynavax Technologies have an RSI of 38.72. Register for free on and access the latest research on DVAX at:

New York-based clinical stage biopharma Company, Anavex Life Sciences Corp.'s stock finished Thursday's session 2.07% higher at $4.44 with a total volume of 275,796 shares traded. The stock is trading below its 50-day moving average by 10.40%. Anavex Life Sciences' stock has an RSI of 45.73. Get free access to your trade alert on AVXL at:

Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA